Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides: Focus Review
Molecular changes in malignant tissue can lead to an increase in the expression levels of
various proteins or receptors that can be used to target the disease. In oncology, diagnostic …
various proteins or receptors that can be used to target the disease. In oncology, diagnostic …
Radiotheranostics: a roadmap for future development
Radiotheranostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid
development over the past decade. Although some formulations are already approved for …
development over the past decade. Although some formulations are already approved for …
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands
K Sjögreen Gleisner, N Chouin, PM Gabina… - European journal of …, 2022 - Springer
The purpose of the EANM Dosimetry Committee is to provide recommendations and
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, R Baum… - European journal of …, 2019 - Springer
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA
B Feuerecker, R Tauber, K Knorr, M Heck, A Beheshti… - European urology, 2021 - Elsevier
Abstract Background Beta-emitting Lu-177-labeled prostate-specific membrane antigen
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor …
C Kratochwil, F Bruchertseifer, H Rathke… - Journal of Nuclear …, 2018 - Soc Nuclear Med
The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed …
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed …
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Purpose: We report efficacy and safety of 90Y-labeled FAPI-46 (90Y-FAPI-46-RLT) in
patients with advanced sarcoma, pancreatic cancer, and other cancer entities. Experimental …
patients with advanced sarcoma, pancreatic cancer, and other cancer entities. Experimental …
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
MP Yadav, S Ballal, RK Sahoo… - American Journal of …, 2019 - Am Roentgen Ray Soc
OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …